US · Healthcare · Biotechnology
EPS came in at -0.30 against a street estimate of -0.30 — a beat of 0.0%.
Analysts rate Lexeo Therapeutics, Inc. Common Stock a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $20.30.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 7.78% |
| Affinity Asset Advisors, LLC | 7.07% |
| BlackRock Inc | 6.99% |
| RA Capital Management, LLC | 6.09% |
| HHG PLC | 6.06% |
| Frazier Life Sciences Management, L.P. | 5.88% |
| State Street Corp | 5.30% |
| Vestal Point Capital LP | 5.26% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexeo Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.